Clinical outcomes of acute stroke patients with atrial fibrillation

Abstract

Evaluation of: Kazumi K, Yasuyuki I, Kensaku S, Takeshi I, Shinji Y, Junya A. IV-tPA therapy in acute stroke patients with atrial fibrillation. J. Neurol. Sci. 276(1–2), 6–8 (2009).

Stroke is the leading cause of disability and the second most common cause of death worldwide. The care and treatment of stroke patients have evolved over the last two decades, with increasing use of thrombolysis (e.g., intravenous tissue plasminogen activator in acute stroke patients), which has improved survival and recovery following stroke. The article under evaluation offers a greater insight into the relationship of clinical outcome of stroke and atrial fibrillation after tissue plasminogen activator infusion.

Keywords::

• atrial fibrillation
• intravenous tissue plasminogen activator
• stroke
• thrombolysis

Financial & competing interests disclosure

Gregory YH Lip has received funding for research, educational symposia, consultancy and lecturing from different manufacturers of drugs used for the treatment of thrombosis, including Astra Zeneca; Bayer; Astellas; and Daichii-Sankyo. He has served on the Executive Steering Committee for Phase II and Phase III clinical trials with new oral anticoagulant drugs for atrial fibrillation and acute coronary syndromes. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those that have been disclosed.

No writing assistance was utilized in the production of this manuscript.